Taken together, these data suggest that BAG-1 may have a prosurvival role in HER2+ cells and further justifies investigating the impact of BAG-1 on the sensitivity of HER2+ cells to trastuzumab and the potential of BAG-1 as a therapeutic target in HER2+ breast cancer. The gene discussed is BAG1; the disease is breast cancer.